Hao Wei, Chief Clinical Researcher

Director of the World Health Organization Collaborating Center and renowned physician from Xiangya, enjoying special government allowances. Professor from Central South University.Member of the United Nations International Narcotics Control Board, elected as First Vice President in 2017 and 2019. Currently serving as the President of the China Association for the Prevention and Treatment of Drug Dependence (Level 1 Association), a member of the World Health Organization Expert Advisory Committee on Drug Dependence and Alcohol Problems, and the main researcher of clinical trials for naltrexone implants.

Li Jin, Scientific Advisor of the Strategic Committee

Professor and doctoral supervisor at the Chinese Academy of Military Medical Sciences; Current Executive Director of the Chinese Pharmacological Society, Vice President of the Chinese Association for the Prevention and Treatment of Drug Abuse, Chairman of the Beijing Neuroscience Society, Executive Director of the Chinese Physiological Society, and Leader of the National 973 Program.

Scientific Advisor of Dan Fengping Strategic Committee

I am a doctoral supervisor and immunology expert at China Medical University, and have been engaged in tumor immunology research in France and the United States for over ten years. Hosted the National Ninth Five Year Science and Technology Public Relations Project and participated in the National 863 High Tech Research and Development Program project jointly undertaken with the Institute of Virology, Chinese Academy of Preventive Medical Sciences.

Wang Wei, Scientific Advisor of the Strategic Committee

Changjiang Scholar, Vice President of the World Association of Chinese Physicians (WACD), Fellow of the Royal College of Medicine (FRSM), Fellow of the School of Public Health of the Royal Society of Physicians (FFPH), Fellow of the Royal Society of Biological Sciences (FRSB), Member of the Expert Committee on Public Health Genomics of the World Health Organization (WHO), Member of the Expert Steering Committee on Public Health Genomics of the Organisation for Economic Co operation and Development (OECD), Australian representative of the European Society for Preventive and Precision Medicine (EPMA), Member of the Expert Committee of the Global Health Epidemiology Working Group (GHERG), and Member of the Organizing Committee of the Human Glycyrome Project (HGP).

Jia Shaowei, Scientific Advisor of the Strategic Committee

Professor at Peking University School of Medicine, Vice Chairman of the Nuclear Medicine Branch of the Chinese Medical Imaging Society, Director of the Nuclear Medicine Branch of the Chinese Nuclear Society, Judge of International Cooperation Projects and 863 Projects of the Ministry of Science and Technology, Editorial Board Member of the National Clinical Technical Operation Standards and Clinical Application Guidelines, and Deputy Editor in Chief of the National Education Ministry's Higher Medical College Textbook "Nuclear Medicine".

Liu Shengjiang, Scientific Advisor of the Strategic Committee

Formerly served as the Director and Chief Scientist of the Pathogen Safety Office in Bayer's Global Biopharmaceutical Research and Development Department. Pursuing a doctoral degree in Biochemistry at Kansas State University in the United States; I am conducting postdoctoral research at Stanford University under the guidance of Dr. Arthur Kornberg, a Nobel laureate in medicine.

Pingqineng Pharmaceutical Formulation Expert

Professor and doctoral supervisor at China Pharmaceutical University; Formerly served as the Dean of the School of Pharmacy at China Pharmaceutical University and Vice Chairman of the Pharmaceutical Professional Committee of the Chinese Pharmaceutical Association. He has been committed to the research of drug sustained and controlled release formulations for a long time, and has made outstanding achievements in the fields of particle delivery systems, transdermal drug delivery, insoluble drug formulations and preparations, drug administration routes and absorption research.

Chief Engineer Wang Shiqiang

Researcher, master's supervisor.
Co founder of Shankang Pharmaceutical and inventor of multiple controlled release implant technology.
Executive Editorial Board Member of the Journal of Central South Pharmacy; Member of the Traditional Chinese Medicine New Drug Evaluation Committee of Hunan Provincial Medical Products Administration, evaluation expert of Hunan Provincial Natural Science Foundation, Hunan Provincial Department of Science and Technology, Hunan Provincial Administration of Traditional Chinese Medicine, and Hunan Provincial Department of Finance. Formerly served as the director of the Traditional Chinese Medicine Preparation Research Laboratory (a third level laboratory of the State Administration of Traditional Chinese Medicine) and the deputy director of the Key Laboratory of Traditional Chinese Medicine New Drug Research and Development in Hunan Province. Former Deputy Director of the Institute of Traditional Chinese Medicine at Hunan University of Traditional Chinese Medicine.
I have hosted multiple national level scientific research projects in Hunan Province and have won the National Science and Technology Progress Award, the first prize of Hunan Science and Technology Progress Award, and the third prize of Hunan Science and Technology Progress Award.

Qu Wei, Chief Technology Officer

PhD in Pharmacology and postdoctoral fellow in Pharmacy at Peking University.
Study abroad at the Department of Molecular Biology, Hokkaido University, Japan.
Leading talents at the local level in Shenzhen, high-level talents in Zhuhai, outstanding young talents in Zhuhai, and council member of the World Federation of Traditional Chinese Medicine.
Formerly served as Vice President of Zhuhai Yisheng Biopharmaceutical Co., Ltd., Senior Researcher at Shandong Bosilen Furuida, Shenzhen Haiwang Biotechnology, and Shanghai Chuangnuo Group, with nearly 100 project development and management experiences.